PROVO, Utah, April 21, 2015 /PRNewswire/ -- Tute Genomics, a leading provider of cloud-based genomic medicine technology, today announced the hiring of Josh Forsythe as VP of Marketing. Mr. Forsythe is the latest to join the company that has witnessed a significant expansion in its commercial operations over the last two quarters.
"Josh Forsythe is a tremendous addition to the Tute Genomics team," stated Reid Robison, MD MBA, CEO of Tute Genomics. "Josh's vast experience commercializing software technology in a highly complex and evolving space, paired with our best-in-class genome analysis solution, will accelerate the adoption of Tute Genomics' precision medicine platform and speed up the use of next-generation sequencing in routine medical care."
Prior to Tute Genomics, Mr. Forsythe held executive sales and marketing positions at two of the most well-respected informatics and genomic interpretation companies over the last decade: Golden Helix, Inc. and Knome, Inc.
"It's exciting and an honor to join Tute Genomics," Mr. Forsythe said. "Not only has the company built a renowned software platform for genomic medicine, but the work the company and its world-class team of personnel and partners have done to expand genomic medicine within the pediatrics and rare disease communities is remarkable. I very much look forward to continuing to help Tute Genomics accelerate the genomic revolution that is transforming the way medicine is practiced and saving lives."
Mr. Forsythe is the latest in a series of commercial announcements by the company upon closing its Series A1 round of funding last December, including the hiring of David Mittelman, PhD as the company's Chief Scientific Officer and Andy Olson, MBA as its VP of Sales, as well as partnerships with Google Genomics and DNA Nexus.
Acknowledgment of the company's and CEO Dr. Robison's achievements and service to the community has also been prevalent. (See Tute Selected as Utah Innovation Award Recipient, Best Utah Health Startup, Company to Watch and CEO Reid Robison named one of UVEF Peak 100.)
"Tute Genomics has long been recognized for the technological advancements in processing, annotation and interpretation of next-generation sequencing data," explained Kai Wang, PhD, President of Tute Genomics. "But it's important for the adoption of precision medicine that these advancements are utilized by hospitals and molecular diagnostic laboratories that are on the frontlines of patient care. We are excited to have Josh as an additional asset to drive this adoption."
About Tute Genomics
Tute Genomics is a Utah-based company that is powering the world's genomic knowledge with a cloud-based solution for precision, genome-guided medicine. Tute provides a clinical genome interpretation platform that helps researchers identify disease genes and biomarkers, and assists clinicians/labs with genetic diagnosis and personalized therapeutics. Tute is built on the expertise that developed ANNOVAR, the most widely used genome annotation and interpretation technology with over 1000 scientific citations. The genome revolution is here, and Tute envisions a future where genome sequencing is part of routine clinical care. Tute integrates genomic data into medical records to give doctors and patients alike access to genetic information at their fingertips where it is most useful and actionable. Genomics is changing healthcare as we know it, and Tute is helping to shape the future of medicine: unlocking the genome, personalizing treatment, and powering discovery. To learn more please visit www.tutegenomics.com and follow us on twitter @TuteGenomics.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tute-genomics-continues-expansion-of-genomic-medicine-commercial-operations-appoints-josh-forsythe-as-new-vp-of-marketing-300068636.html
SOURCE Tute Genomics